ArticleInternal medicine (Tokyo, Japan)2019
Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- [Histological Transformation from Non-small Cell Lung Cancer to Small Cell Lung Cancer Induced by Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Pooled it
- [Research Progress on the Potential Mechanisms of Hyper-progressive Disease in Immune Checkpoint Blockade Therapy of Solid Tumors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- [Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Article
- Review
- A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy.Thoracic cancer · 2025Article
- Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review.Frontiers in immunology · 2024Review
- Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.Frontiers in immunology · 2023Review
- Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.Frontiers in immunology · 2023Review
- Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases.Frontiers in oncology · 2022Article
- Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review.Thoracic cancer · 2021Review
- Small cell lung cancer transformation during antitumor therapies: A systematic review.Open medicine (Warsaw, Poland) · 2021Review
- Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.Frontiers in pharmacology · 2021Review
- Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?Journal for immunotherapy of cancer · 2020Article
- Review
- Histologic transformation of lung cancer during pembrolizumab therapy: A case report.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperprogressive disease (HPD) is a paradoxical phenomenon involving the acceleration of tumor progression after treatment with immune checkpoint inhibitors (ICIs). A 66-year-old male smoker with advanced lung adenocarcinoma started pembrolizumab for progressive disease following first-line chemotherapy. He developed HPD after two cycles, and a re-biopsy revealed transformation to small-cell carcinoma. He subsequently underwent two lines of chemotherapy for small-cell carcinoma until progression and ultimately died. Transformation to small-cell carcinoma may be a cause of HPD during ICI therapy. The possibility of pathological transformation should be considered in cases of HPD with resistance to ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.